BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Update

BioLineRx Ltd. (NASDAQ:BLRX) saw a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 1,060,000 shares, a growth of 70.6% from the October 15th total of 621,400 shares. Based on an average trading volume of 303,100 shares, the short-interest ratio is presently 3.5 days.

Institutional Investors Weigh In On BioLineRx

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BLRX. CVI Holdings LLC purchased a new position in BioLineRx during the second quarter valued at approximately $462,000. PVG Asset Management Corp purchased a new position in shares of BioLineRx during the 2nd quarter valued at approximately $70,000. Finally, Atria Investments Inc lifted its stake in shares of BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 29,193 shares during the period. 1.56% of the stock is owned by institutional investors and hedge funds.

BioLineRx Stock Performance

Shares of BLRX stock opened at $0.45 on Thursday. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.61 and a quick ratio of 1.49. The business has a fifty day moving average of $0.52 and a 200 day moving average of $0.62. The firm has a market capitalization of $36.29 million, a price-to-earnings ratio of -1.01 and a beta of 1.48. BioLineRx has a 1 year low of $0.39 and a 1 year high of $1.93.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings results on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. The business had revenue of $5.39 million for the quarter, compared to analysts’ expectations of $3.93 million. As a group, research analysts expect that BioLineRx will post -0.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BLRX. StockNews.com assumed coverage on BioLineRx in a research report on Friday, November 8th. They set a “hold” rating on the stock. HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of BioLineRx in a research note on Wednesday, November 6th.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.